# Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

> **NCT00035334** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 150 (—)

## Conditions studied

- Secondary (AA) Amyloidosis
- Rheumatoid Arthritis
- Nephrotic Syndrome
- Familial Mediterranean Syndrome
- Kidney Diseases
- Gastrointestinal Diseases

## Interventions

- **DRUG:** NC-503 (Anti-amyloidotic (AA) Agent)

## Key facts

- **NCT ID:** NCT00035334
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 150 (—)
- **Last updated:** 2006-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035334, "Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00035334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*